| Segment Reporting Disclosure [Text Block] |
(10) Segment Information
The Company’s reportable segments are reported in a manner consistent with the way management evaluates the businesses. The results of operations are regularly reviewed by the Company's chief operating decision maker ("CODM"), the Chief Executive Officer. The Company identifies its reportable business segments based on differences in products and services. The accounting policies of the business segments are the same as those described in the summary of significant accounting policies. In order to evaluate each reportable segment's performance, the CODM uses income from operations as a measure of profit and loss. The CODM compares operational performance against management expectations when making decisions regarding allocation of operating and capital resources to each segment.
In 2025, the Company has five reportable segments which include: Theranostics Products, Cobalt Products, Nuclear Medicine Standards, Medical Device Products, and Fluorine Products. Information regarding the operations and assets of these reportable business segments is contained in the following table:
| | | Three months ended June 30, | | | Six months ended June 30, | |
| Sale of Product | | 2025 | | | 2024 | | | 2025 | | | 2024 | |
| Theranostics Products | | $ | 1,905,402 | | | $ | 2,169,131 | | | $ | 3,692,456 | | | $ | 4,074,213 | |
| Cobalt Products | | | 678,015 | | | | 592,199 | | | | 750,465 | | | | 826,167 | |
| Nuclear Medicine Standards | | | 1,013,814 | | | | 407,903 | | | | 2,340,580 | | | | 1,173,311 | |
| Medical Device Products | | | 58,089 | | | | — | | | | 110,719 | | | | — | |
| Fluorine Products | | | — | | | | — | | | | — | | | | — | |
| Total Segments | | | 3,655,320 | | | | 3,169,233 | | | | 6,894,220 | | | | 6,073,691 | |
| Corporate revenue | | | — | | | | — | | | | — | | | | — | |
| Total Consolidated | | $ | 3,655,320 | | | $ | 3,169,233 | | | $ | 6,894,220 | | | $ | 6,073,691 | |
| | | Three months ended June 30, | | | Six months ended June 30, | |
| Depreciation and Amortization | | 2025 | | | 2024 | | | 2025 | | | 2024 | |
| Theranostics Products | | $ | 9,895 | | | $ | 5,697 | | | $ | 18,104 | | | $ | 14,743 | |
| Cobalt Products | | | 16,360 | | | | 23,527 | | | | 32,362 | | | | 27,414 | |
| Nuclear Medicine Standards | | | 31,480 | | | | 32,866 | | | | 61,360 | | | | 61,419 | |
| Medical Device Products | | | — | | | | — | | | | — | | | | — | |
| Fluorine Products | | | 26,095 | | | | 26,095 | | | | 52,190 | | | | 57,940 | |
| Total Segments | | | 83,830 | | | | 88,185 | | | | 164,016 | | | | 161,516 | |
| Corporate depreciation and amortization | | | 17,207 | | | | 10,790 | | | | 34,966 | | | | 38,906 | |
| Total Consolidated | | $ | 101,037 | | | $ | 98,975 | | | $ | 198,982 | | | $ | 200,422 | |
| | | Three months ended June 30, | | | Six months ended June 30, | |
| Segment Income (Loss) | | 2025 | | | 2024 | | | 2025 | | | 2024 | |
| Theranostics Products | | $ | 1,009,387 | | | $ | 1,171,390 | | | $ | 1,886,381 | | | $ | 2,184,854 | |
| Cobalt Products | | | (97,040 | ) | | | 99,324 | | | | (245,266 | ) | | | 32,999 | |
| Nuclear Medicine Standards | | | (38,387 | ) | | | (377,758 | ) | | | 229,176 | | | | (368,262 | ) |
| Medical Device Products | | | (201,305 | ) | | | (83,839 | ) | | | (382,974 | ) | | | (112,350 | ) |
| Fluorine Products | | | 3,905 | | | | (26,095 | ) | | | (22,254 | ) | | | (4,846 | ) |
| Total Segments | | | 676,560 | | | | 783,022 | | | | 1,465,063 | | | | 1,732,395 | |
| Corporate loss | | | (837,345 | ) | | | (1,016,467 | ) | | | (1,738,542 | ) | | | (2,119,891 | ) |
| Net Income | | $ | (160,785 | ) | | $ | (233,445 | ) | | $ | (273,479 | ) | | $ | (387,496 | ) |
| | | Three months ended June 30, | | | Six months ended June 30, | |
| Expenditures for Segment Assets | | 2025 | | | 2024 | | | 2025 | | | 2024 | |
| Theranostics Products | | $ | 4,046 | | | $ | — | | | $ | 50,561 | | | $ | 93,924 | |
| Cobalt Products | | | — | | | | 39,799 | | | | 12,835 | | | | 39,799 | |
| Nuclear Medicine Standards | | | 57,449 | | | | — | | | | 75,663 | | | | 49,038 | |
| Medical Device Products | | | — | | | | — | | | | 28,876 | | | | — | |
| Fluorine Products | | | — | | | | — | | | | — | | | | — | |
| Total Segments | | | 61,495 | | | | 39,799 | | | | 167,935 | | | | 182,761 | |
| Corporate purchases | | | — | | | | 4,216 | | | | 22,439 | | | | 32,175 | |
| Total Consolidated | | $ | 61,495 | | | $ | 44,015 | | | $ | 190,374 | | | $ | 214,936 | |
| | | June 30, | | | December 31, | |
| Segment Assets | | 2025 | | | 2024 | |
| Theranostics Products | | $ | 1,358,808 | | | $ | 992,513 | |
| Cobalt Products | | | 122,282 | | | | 167,881 | |
| Nuclear Medicine Standards | | | 2,649,344 | | | | 2,928,814 | |
| Medical Device Products | | | 653,882 | | | | 553,117 | |
| Fluorine Products | | | 4,823,549 | | | | 4,875,738 | |
| Total Segments | | | 9,607,865 | | | | 9,518,063 | |
| Corporate assets | | | 7,902,234 | | | | 7,642,905 | |
| Total Consolidated | | $ | 17,510,099 | | | $ | 17,160,968 | |
|